| Atrial Fibrillation
Sotylize vs Multaq
Side-by-side clinical, coverage, and cost comparison for atrial fibrillation.Deep comparison between: Sotylize vs Multaq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMultaq has a higher rate of injection site reactions vs Sotylize based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Multaq but not Sotylize, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotylize
Multaq
At A Glance
Oral
Twice daily
Class II/III antiarrhythmic
Oral
Twice daily
Multi-class antiarrhythmic
Indications
- Ventricular arrhythmia
- Atrial Fibrillation
- Atrial Flutter
- Atrial Fibrillation
Dosing
Ventricular arrhythmia Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days to a maximum 320 mg/day, with therapeutic response typically at 160-320 mg/day in two or three divided doses.
Atrial Fibrillation, Atrial Flutter Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days provided QTc <500 msec; most patients respond at 120 mg twice daily.
Atrial Fibrillation 400 mg twice daily orally; one tablet with the morning meal and one tablet with the evening meal.
Contraindications
- Baseline QT interval >450 msec
- Sinus bradycardia, sick sinus syndrome, or second and third degree AV block without a functioning pacemaker
- Congenital or acquired long QT syndromes
- Cardiogenic shock or decompensated heart failure
- Hypokalemia
- Bronchial asthma or related bronchospastic conditions
- Hypersensitivity to sotalol
- Permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored)
- Symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV symptoms
- Second or third-degree atrioventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker)
- Bradycardia
- Concomitant use of strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir)
- Concomitant use of erythromycin
- Concomitant use of QT-prolonging drugs or herbal products (phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, Class I and III antiarrhythmics)
- Liver or lung toxicity related to previous use of amiodarone
- QTc interval >500 ms or PR interval >280 ms
- Severe hepatic impairment
- Hypersensitivity to the active substance or to any of the excipients
Adverse Reactions
Most common (>=2%) Fatigue, bradycardia, dyspnea, proarrhythmia, asthenia, dizziness.
Serious Sustained ventricular tachycardia/ventricular fibrillation, Torsade de Pointes.
Postmarketing Emotional liability, slightly clouded sensorium, incoordination, vertigo, paralysis, thrombocytopenia, eosinophilia, leukopenia, photosensitivity reaction, fever, pulmonary edema, hyperlipidemia, myalgia, pruritus, alopecia.
Most common (>=1%) Diarrhea, nausea, abdominal pain, vomiting, dyspepsia, asthenia, bradycardia, skin rash
Serious New or worsening heart failure, liver injury, pulmonary toxicity, QT prolongation, hypokalemia and hypomagnesemia with potassium-depleting diuretics
Postmarketing New or worsening heart failure, atrial flutter with 1:1 AV conduction, liver injury, interstitial lung disease (pneumonitis, pulmonary fibrosis), anaphylactic reactions including angioedema, vasculitis including leukocytoclastic vasculitis
Pharmacology
Sotalol is a non-cardioselective beta-adrenoreceptor blocker (Vaughan Williams Class II) with cardiac action potential duration prolongation (Class III) antiarrhythmic properties; it slows heart rate, decreases AV nodal conduction, and increases refractory periods of atrial and ventricular muscle and conduction tissue.
Dronedarone is an antiarrhythmic agent with properties belonging to all four Vaughan-Williams classes (I, II, III, and IV), though the mechanism of action and contribution of each class to the clinical effect is unknown; it also acts as a moderate inhibitor of CYP3A and CYP2D6 and inhibits P-glycoprotein transport.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotylize
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Multaq
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Sotylize
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (0/8)
Multaq
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Sotylize
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Multaq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Cardiac Arrhythmias
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Multaq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotylizeView full Sotylize profile
MultaqView full Multaq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.